Bristol-Myers Squibb, Strong Buy
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. BMY rose 3.67% to $57.88 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.08% to 43,461.21 and the S&P 500 Index SPX falling 0.50% to 5,983.25. This was the stock's fifth consecutive day of gains.
Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.
The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...
William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...
Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note ...
20h
Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...
Hosted on MSN4d
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board?JPMorgan is sticking with Eli Lilly (LLY) as its top biopharma pick for 2025, while also highlighting Gilead Sciences (GILD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback